Microelectrode arrays (MEAs) have been in use over the past decade and a half to study
multiple aspects of electrically excitable cells. In particular, MEAs have been applied to …

Microfluidic technologies' ability to miniaturize assays and increase experimental throughput
have generated significant interest in the drug discovery and development domain. These …

Background Neuronal degeneration in multiple sclerosis has been linked to oxidative stress.
Dimethyl fumarate is a promising novel oral therapeutic option shown to reduce disease …

Predicting human safety risks of novel xenobiotics remains a major challenge, partly due to
the limited availability of human cells to evaluate tissue-specific toxicity. Recent progress in …

Neuronal assemblies within the nervous system produce electrical activity that can be
recorded in terms of action potential patterns. Such patterns provide a sensitive endpoint to …

Drug-induced seizure liabilities produce significant compound attrition during drug
discovery. Currently available in vitro cytotoxicity assays cannot predict all toxicity …

The desire to develop and evaluate drugs as potential countermeasures for biological and
chemical threats requires test systems that can also substitute for the clinical trials normally …

Multi-channel acquisition from neuronal networks, either in vivo or in vitro, is becoming a
standard in modern neuroscience in order to infer how cell assemblies communicate. In …

Many drug discovery screening programs employ immortalized cells, recombinantly
engineered to express a defined molecular target. Several technologies are now emerging …

In vitro neuronal cultures exhibit spontaneous electrophysiological activity that can be
modulated by chemical stimulation and can be monitored over time by using Micro …